Who Paid My Doc
David Lowenberg
Orthopaedic Trauma San Francisco, CA Medical Doctor
NPI 1992746150 CMS profile 45032
2100 Webster St, Suite 117, San Francisco, CA 94115
General payments
$788,385
Research payments
$0
Ownership & investment interest
$375,002
Through program year 2025, David Lowenberg of San Francisco, CA is reported in the CMS Open Payments database as having received $788,385 across 41 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $375,002 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $510 | 4 | |
| 2024 | General | $2,740 | 14 | |
| 2023 | General | $2,117 | 2 | |
| 2022 | General | $774,792 | 3 | |
| 2021 | General | $1,000 | 1 | |
| 2020 | General | $64 | 1 | |
| 2019 | General | $7,162 | 16 | |
| 2021 | Ownership | $375,002 | 1 |
Beside peers
- David Lowenberg
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to David Lowenberg were reported at $510. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | David Lowenberg | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,162 | $1,475 | $264–$6,401 | $163 |
| 2020 | $64 | $596 | $120–$4,020 | $114 |
| 2021 | $1,000 | $919 | $171–$4,697 | $132 |
| 2022 | $774,792 | $1,547 | $272–$7,240 | $149 |
| 2023 | $2,117 | $1,330 | $247–$5,875 | $160 |
| 2024 | $2,740 | $1,288 | $277–$6,797 | $164 |
| 2025 | $510 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$11,983
Medicare patients
37
Services billed
57
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 70% | |
| Diabetes | 30% | |
| Cancer | 30% | |
| Depression | 30% | |
| Osteoporosis | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
41 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in California
Related records
Orthopaedic Trauma in California
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.